Extension Study of PF‐05280586, a Potential Rituximab Biosimilar, Versus Rituximab in Subjects With Active Rheumatoid Arthritis

OBJECTIVE: This extension study provided continued treatment to subjects with active rheumatoid arthritis who had participated for ≥16 weeks in a pharmacokinetic similarity study of PF‐05280586 (potential rituximab biosimilar). Objectives were to evaluate overall pharmacokinetics, pharmacodynamics,...

Descripción completa

Detalles Bibliográficos
Autores principales: Cohen, Stanley B., Burgos‐Vargas, Rubén, Emery, Paul, Jin, Bo, Cronenberger, Carol, Vázquez‐Abad, María‐Dolores
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2018
Materias:
Rheumatoid Arthritis
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6221032/
https://www.ncbi.nlm.nih.gov/pubmed/29692005
http://dx.doi.org/10.1002/acr.23586

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6221032/
https://www.ncbi.nlm.nih.gov/pubmed/29692005
http://dx.doi.org/10.1002/acr.23586

Ejemplares similares